Spots Global Cancer Trial Database for Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Studying Genes Using Cord Blood and Placenta Samples From Relatively Healthy Newborns and Samples From Younger Patients With Wilms Tumor

Official Title: Investigating the Frequency of Loss of Imprinting Across a Birth Cohort and the Link DNA Methylation Plays

Study ID: NCT01576211

Conditions

Kidney Cancer

Interventions

DNA methylation analysis

RNA analysis

allele-specific oligonucleotide real-time quantitative polymerase chain reaction

gene expression analysis

nucleic acid sequencing

polymorphism analysis

laboratory biomarker analysis

Study Description

Brief Summary: RATIONALE: Studying samples of blood and tissue from newborns and from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies cord blood and placenta tissue from newborns, and tumor tissue samples from patients with Wilms tumor.

Detailed Description: OBJECTIVES: * What is the frequency of loss of imprinting at birth (in the cord blood and placenta) in a relatively healthy birth cohort? * Does deoxyribonucleic acid (DNA) methylation levels at imprinting genes have a direct association to the gene expression? OUTLINE: Archived tumor tissue, cord blood, and placenta samples are analyzed for DNA methylation, single nucleotide polymorphism, and gene expression by polymerase chain reaction (PCR), pyrosequencing, and quantitative real-time PCR. Information regarding gender and age of the samples are also collected, if possible.